EIF2AK3

Across TCGA pan-cancer cohorts, EIF2AK3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF2AK3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher EIF2AK3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2AK3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and SKCM are the cancer types where EIF2AK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	36	view →
UCEC	DFS	Median	All	0.966	0.607	.002	32	view →
SKCM	OS	Median	All	0.202	0.784	<.001	17	view →
BLCA	DFS	Median	III,IV	0.155	0.576	.001	6	view →
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF2AK3–CESC (DFS)

Open the CESC breakdown →